CBL0137 is a metabolically stable curaxin that activates p53 (EC50 = 0.37 μM) and inhibits NF-κB (EC50 = 0.47 μM). It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death. CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates efficacy of gemcitabine (Cat. No.1759 in preclinical models of pancreatic cancer. MW: 336.4. Purity ≥98% by HPLC